Search

Search Results

• ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

  Alessandro Busca, Livio Pagano

  e2016039

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.039

  4705

  PDF: 1545

  HTML: 2250

  Untitled: 204

  Untitled: 219

  Untitled: 228

  Untitled: 210

  Untitled: 212

• Massive pulmonary embolism at the onset of acute promyelocytic leukemia

  Federica Sorà, Patrizia Chiusolo, Luca Laurenti

  e2016027

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.027

  3492

  PDF: 871

  HTML: 1650

  figure 1: 161

  Untitled: 187

• Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax

  Claudio Fozza

  e2024011

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.011

  1599

  PDF: 1331

  HTML: 174

• Hyperbilirubinemia in abo minor mismatch transplantation.

  xiaolin yin

  e2024050

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.050

  498

  PDF: 669

  HTML: 73

• The possible role of chronic infection in the etiopathogenesis of a case of 5q-syndrome associated with tuberculosis and abnormality of the X chromosome.

  Lubomir Mitev

  e2022079

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.079

  1371

  PDF: 475

  HTML: 255

• THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

  Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori

  e2012022

  2012-04-06

  https://doi.org/10.4084/mjhid.2012.022

  2164

  PDF: 875

  HTML: 1938

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2265

  PDF: 772

  HTML: 817

• ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTS

  Anna Maria Testi, Francesco Lococo

  e2014032

  2014-04-15

  https://doi.org/10.4084/mjhid.2014.032

  2729

  PDF: 1656

  HTML: 2258

• Hematogenous Disseminated Pulmonary Tuberculosis in an Elderly Patient with Acute Myeloid Leukemia: A Case Report

  Yu xi Ding, Xiao Dong Liu, wenqiang kong

  e2026010

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.010

  516

  PDF: 453

  HTML: 203

• ASSOCIATION BETWEEN LEUKEMIC EVOLUTION AND UNCOMMON CHROMOSOMAL ALTERATIONS IN PEDIATRIC MYELODYSPLASTIC SYNDROME

  Viviane Lamim Lovatel, Beatriz Ferreira da Silva , Eliane Ferreira Rodrigues , Maria Luiza Rocha da Rosa Borges , Rita de Cássia Barbosa Tavares, Ana Paula Silva Bueno, Elaine Sobral da Costa, Terezinha de Jesus Marques , Teresa de Souza Fernandez

  e2024003

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.003

  1161

  PDF: 1368

  HTML: 129

• Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report

  Martina Di Palma, Elio Gentilini, Chiara Masucci, Alessandra Micozzi, Ombretta Turriziani, Antonino Mulè, Robin Foà, Maurizio Martelli, Gabriella D'Ettorre, Saveria Capria, Sabina Chiaretti

  e2022043

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.043

  1315

  PDF: 566

  HTML: 215

• The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones

  Antonio Cristiano, Raffaele Palmieri, Emiliano Fabiani, Tiziana Ottone, Mariadomenica Divona, Arianna Savi, Francesco Buccisano, Luca Maurillo, Corrado Tarella, William Arcese, Maria Teresa Voso

  e2022041

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.041

  1211

  PDF: 754

  HTML: 308

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2125

  PDF: 727

  HTML: 1625

• Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

  Edoardo Olivari

  e2025040

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.040

  1020

  PDF: 763

  HTML: 149